2013
DOI: 10.2310/7750.2013.13012
|View full text |Cite
|
Sign up to set email alerts
|

Successful Treatment of Necrobiotic Xanthogranuloma with Intravenous Immunoglobulin

Abstract: Background: Necrobiotic xanthogranuloma (NXG) is a rare chronic disorder characterized by firm yellow to red-orange nodules and plaques affecting the face, abdomen, and extremities with the potential for systemic involvement. NXG has a close association with monoclonal gammopathies, and there is a predilection for the development of multiple myeloma. Treatment options are varied due to inconsistent results seen with the use of corticosteroids, immunomodulators, chemotherapeutic agents, and antibiotics.Objectiv… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
15
0
2

Year Published

2014
2014
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 20 publications
(17 citation statements)
references
References 17 publications
0
15
0
2
Order By: Relevance
“…Surgical excision, apart from being impracticable in many cases such as ours, carries a considerable relapse rate . According to recent studies , IVIg therapy may be a valuable alternative in refractory NXG with an acceptable safety profile including in women of child‐bearing age. The rationale for IVIg use is based on the assumption that NXG is triggered by an immune response to paraproteinemia, and thus immunomodulatory effects of IVIg may be helpful .…”
mentioning
confidence: 94%
“…Surgical excision, apart from being impracticable in many cases such as ours, carries a considerable relapse rate . According to recent studies , IVIg therapy may be a valuable alternative in refractory NXG with an acceptable safety profile including in women of child‐bearing age. The rationale for IVIg use is based on the assumption that NXG is triggered by an immune response to paraproteinemia, and thus immunomodulatory effects of IVIg may be helpful .…”
mentioning
confidence: 94%
“…It is important to note that IVIG was well tolerated with no associated adverse events noted in our patients. Recently, there have been two published articles in the literature demonstrating the successful use of IVIG to treat NXG refractory to conventional therapies (7,8). The three patient cases presented in these articles all had documented paraproteinemia; however, we had success with IVIG in one patient with and one without paraproteinemia, suggesting it may be effective in both types.…”
Section: Discussionmentioning
confidence: 90%
“…Unter sorgfältiger Risiko‐Nutzen‐Abwägung und unter Berücksichtigung publizierter Fallberichte begannen wir die Therapie mit intravenösen Immunglobulinen (IVIG) 2 g/kgKG über 4 Tage im Abstand von 6 Wochen. Nach zwei Zyklen zeigte sich noch keine wesentliche Befundbesserung und der Patient wurde zur Re‐Evaluation erneut in der Hämatologie vorgestellt.…”
Section: Therapie Und Verlaufunclassified
“…Intravenöse Immunglobuline (IVIG) sind bislang nicht zur Behandlung in der Dermatologie zugelassen. Dennoch gibt es Publikationen zum erfolgreichen Einsatz beim NXG, wenngleich die Wirkung nicht voll verstanden ist . Therapieversuche mit Melphalan, Dapson und Cyclophosphamid sind in der Literatur mit mäßigem Ansprechen beschrieben.…”
Section: Kommentarunclassified